THE WIRE · № 63678
SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 2026
01 THE MACHINE READ
WHY IT MATTERS.
Continuous glucose sensing tied to automated insulin delivery could expand the diabetes device market, but this is a conference presentation with no commercial terms.
Device makers compete on sensing-to-dosing integration
Regulatory filings or trial data after EASD
No commercial timeline or approval disclosed
FULL DISPATCH
MILAN, Oct. 4, 2026 /PRNewswire/ -- At the European Association for the Study of Diabetes (EASD) 2026, SiBionics presented "See More, Act Earlier," connecting continuous sensing with future diabetes care. Three exhibition chapters shaped this vision: "See More: Beyond Glucose," covering...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
Supreme Court denies Arizona’s bid to delay start of takeover of healthcare in state prisons2026-10-02 16:22 UTC
Integra LifeSciences Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Integra LifeSciences (IART)2026-10-02 22:42 UTC
Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 20262026-10-03 00:30 UTC
Trump finally taps fund, along with favored nations deals, to significantly cut costs for seniors2026-10-03 02:59 UTC
Aetna 2027 Medicare plans offer reliable, affordable access to care & member support2026-10-03 11:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.